Kleo Pharmaceuticals Inc., a New Haven, CT-based biotechnology company, secured a Series A funding of undisclosed amount.
The round was led by Biohaven Pharmaceutical Holding Company.
The company intends to use the funds to advance the development of Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs).
Founded by Dr. David Spiegel and Roy Prieb, Kleo Pharmaceuticals is a biotechnology company advancing a new class of immunotherapies utilizing small molecules to activate an individual’s own immune system to fight against cancers and infectious diseases.
ARMs are bifunctional or ‘two-headed’ chemical structures designed such that one head interacts with disease-relevant molecular targets (such as cancers), while the other head interacts directly with antibodies already present in a person’s bloodstream.
SyAMs are novel synthetic molecules that possess both the targeting and effector cell activating functions of antibodies.
The new drugs being developed by Kleo recruit the immune system to target and kill disease specific cells.